• Vaccine Name: rMV-SARS-CoV-S/Ssol
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Vaccine Ontology ID: VO_0004711
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Description: A live attenuated recombinant meas(Escriou et al., 2014)s vaccine (MV) candidates expressing either the membrane-anchore SARS-CoV spike (S) protein (Escriou et al., 2014).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001056
• Preparation: Live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol) (Escriou et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: CD46-IFNAR (Escriou et al., 2014)
• Host age: 8-12 weeks (Escriou et al., 2014)
• Host gender: Male (Escriou et al., 2014)
• Vaccination Protocol: Mice were immunized with two intraperitoneal (i.p.) injections at 4-week interval of 10^5 TCID50 of MV-S or MV-Ssol recombinant viruses (Escriou et al., 2014).
• Vaccine Immune Response Type: VO_0003057
• Immune Response: Production of anti-SARS IgG (specifically IgG2a) after 1 dose, increased by 10-20 fold after second dose. Induced production of neutralizing antibodies, as well as moderate levels of anti-SARS IgA antibodies (Escriou et al., 2014)
• Challenge Protocol: Mice were inoculated intranasally with 105 pfu of SARS-CoV five weeks after the second immunization (Escriou et al., 2014).
• Efficacy: Recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV (Escriou et al., 2014).